Context Therapeutics Inc.
CNTX
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across femaleā¦ read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$0.50
Price-3.77%
-$0.02
1Y
Price
Market Cap
$45.949m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$40.227m
-11.4%
1y CAGR-19.3%
3y CAGR-29.9%
5y CAGREPS
-$0.42
-10.5%
1y CAGR+25.4%
3y CAGR+3.7%
5y CAGRBook Value
$52.202m
$58.859m
Assets$6.657m
Liabilities$282.420k
DebtDebt to Assets
0.5%
-
Debt to EBITDAFree Cash Flow
-$32.824m
-24.2%
1y CAGR-17.9%
3y CAGR-25.8%
5y CAGRNo items found.
Press Releases
Statements and updates from the company